N/A N=437 OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Opioid-use Disorder
Primary: Treatment Success Rate — 70; 67 Participants — p=0.7326
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=105 Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
Opioid-use Disorder
Primary: Adherence to Medication Assisted Treatment (MAT) — 32; 17 Participants
N/A N=19 mHealth for Patient Self-Management of Opioid Use Disorder
Opioid-use Disorder
Primary: Usability Score — 89.5 score on a scale
Phase 2 N=47 A Multiple Dose Opioid Challenge Study
Moderate or Severe Opioid Use Disorder
Primary: Treatment Phase Drug Liking Visual Analog Scale (VAS) Emax Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w…
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
Phase 4 N=17 SUBLOCADE Rapid Initiation Extension Study
Opioid Use Disorder, Severe · Opioid Use Disorder, Moderate
Primary: Treatment Emergent Adverse Event (TEAE) Occurrence — 0 Participants
Phase 3 N=49 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants
N/A N=254 Collaborating to Heal Addiction and Mental Health in Primary Care
Opioid-use Disorder · Mental Health Disorder
Primary: Opioid Use Other Than As Prescribed — 3.92; 0.72 Days — p=<0.001
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=55 Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
Opioid-use Disorder
Primary: Intervention PCP Confidence in Assessing and Treating OUD — 6; 11; 8; 1 Participants
Phase 3 N=20 Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Substance-Related Disorders · Substance Use Disorders · Substance Abuse, Intravenous
Primary: Opioid Craving Using Visual Analogue Scale — 3.909; 6; 4.556; 5.5 score on a scale
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
N/A N=63 Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment
Opioid Medication Assisted Treatment
Primary: Number of Patients Within Participating Sites With OUD Initiating MOUD During the Implementation Facilitation Period in Implementation Sites. This Will be Compared to…
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
N/A N=16 Usability Testing for the Reward-based Technology to Improve OUD Treatment
Opioid-use Disorder · Contingency Management · Medication for Opioid-use Disorder
Primary: OARSCM Usability - Phase 1 Usability — 12 Participants
N/A N=155 Technology for MAT in Primary Care - Phase 2
Opioid-use Disorder
Primary: Urine Drug Screening Test Results — 92.3; 92.0; 1.9; 2.0 percentage of participants positive
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 3 N=665 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Opioid Dependence · Opioid Related Disorders
Primary: Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From…
N/A N=375 Contingency Management to Enhance Office-Based Buprenorphine Treatment
Opioid-use Disorder
Primary: Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples — 80; 84; 78 percentage of urine samples — p==0.22
Phase 2 N=30 Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
N/A N=32 CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder
Opioid-use Disorder · Medication Adherence · Health Care Utilization
Primary: Number of Missed Medication Doses - Past 30 Days — 3.13; 2.81; 3.71; 2.25 Number of missed doses — p=0.17
Phase 2 N=39 Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
Opioid Use Disorder
Primary: Opioid Blockade Following Administration of Hydromorphone Challenge As Measured Using the Subjective Opioid Effects Rating for the Question "Do You Like the Drug?"…
N/A N=102 Optimizing Pregnancy and Treatment Interventions for Moms 2.0
Pregnancy, High Risk · Opioid-Related Disorders · Pregnancy Related
Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days
N/A N=63 Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
Opioid-use Disorder · Anxiety Disorders · Depressive Disorder
Primary: Change in Anxiety Symptoms as Assessed by Generalized Anxiety Disorder- Q-IV Scale — -1.8; -1.04; -2.47; -1.53 units on a scale — p=.755
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
N/A N=171 Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)
Opioid-use Disorder
Primary: Number of Participants With Retention in Medication Treatment for OUD — 46; 51 Participants — p=0.94
Phase 3 N=9 Buprenorphine Treatment for Opioid Dependence
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants